Skip to main content
Premium Trial:

Request an Annual Quote

LJL Biosystems Ships Its Analyst HTS Product To Millennium Pharma

Premium

SUNNYVALE, Calif.--LJL Biosystems here announced last week that it has released its new high-throughput screening product, the Analyst, for commercial shipments. The product is expected to enable drug discovery labs to perform multiple assays with increased throughput sensitivity and reduced costs per assay, and is designed to perform 5-10 million assays per year, the company said. The first commercial shipment of the Analyst was to Millennium Pharmaceuticals. LJL CEO Lev Leytes said he believes the new technology will fundamentally change the drug discovery process by providing scientists with a more efficient, less costly assay detection process.

Filed under

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.